Next-Gen CAR-Tregs
Multiple Sclerosis (MS)
Key Facts
About PolTREG
PolTREG is a clinical-stage biotech leveraging over 17 years of foundational research to develop Treg-based therapies for autoimmune diseases, with the goal of restoring immune tolerance. Its lead asset, PTG007, is in clinical trials for Type 1 Diabetes and Multiple Sclerosis, and the company is building a next-generation pipeline of engineered CAR-Tregs. Strategically, PolTREG aims to become a global leader in the field, supported by its proprietary manufacturing capabilities and a clear path to seek partnerships with major pharmaceutical companies for commercialization.
View full company profileAbout PolTREG
PolTREG is a clinical-stage biotech leveraging over 17 years of foundational research to develop Treg-based therapies for autoimmune diseases, with the goal of restoring immune tolerance. Its lead asset, PTG007, is in clinical trials for Type 1 Diabetes and Multiple Sclerosis, and the company is building a next-generation pipeline of engineered CAR-Tregs. Strategically, PolTREG aims to become a global leader in the field, supported by its proprietary manufacturing capabilities and a clear path to seek partnerships with major pharmaceutical companies for commercialization.
View full company profileTherapeutic Areas
Other Multiple Sclerosis (MS) Drugs
| Drug | Company | Phase |
|---|---|---|
| CYMS101 | FibroBiologics | Preclinical |
| Alpha-Cobratoxin (Pharmaceutical) | Nutra Pharma | Preclinical |
| CNM-Au8 | Clene | Phase 2 |
| Sequential Dialysis Technique | Halberd | Discovery |
| MS Treatment (with Cycle Vita) | Cycle Pharmaceuticals | Commercial |
| GM6 | Genervon Biopharmaceuticals | Planning |
| MS Biomarker Development | Progentec Diagnostics | Pre-clinical/R&D |
| XT-150 (Preclinical) | Xalud Therapeutics | Preclinical |
| MEK Inhibitor Program | Pasithea Therapeutics | Discovery |